Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

March 16, 2026 - 18:22

Cue Biopharma has released its financial and operational results for the fourth quarter and full year ending 2025, detailing a period marked by strategic pipeline advancement and key corporate developments. The company highlighted significant progress with its lead therapeutic candidate, CUE-401, which is being prepared for Investigational New Drug (IND) application submission. This asset is a central component of the company's strategy to treat challenging autoimmune and inflammatory disorders.

The year also saw important leadership and financial milestones. Cue Biopharma strengthened its executive team with the appointment of Lucinda Warren, an experienced industry veteran, to the role of Chief Financial and Business Officer. To support its ongoing research, the company successfully raised net proceeds of $10.2 million via a public offering, bolstering its financial position.

A major strategic highlight was the formation of a new collaboration with ImmunoScape. This partnership is focused on pioneering a novel cell therapy approach aimed at treating solid tumors. As part of this agreement, Cue Biopharma is entitled to receive an upfront payment, combining financial support with innovative research to expand its oncology portfolio. The company's reported financial results reflect a continued investment in these core research and development initiatives as it advances its pipeline toward clinical milestones.